Form 4: Arteris VP Sells Shares Under 10b5-1 Plan

Arteris, Inc.'s VP and General Counsel, Paul L. Alpern, sold 5,000 shares of common stock for over $10 per share after exercising options.

Summary

• Paul L. Alpern, VP and General Counsel of Arteris, Inc. (AIP), reported an exercise of derivative securities and a subsequent sale of common stock on October 1, 2025.
• Alpern acquired 5,000 shares of common stock by exercising derivative securities at a price of $0.56 per share.
• Concurrently, Alpern disposed of 5,000 shares of common stock at a weighted average sale price of $10.3089 per share, with individual transactions ranging from $10.16 to $10.51.
• These transactions were executed pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2025.
• Following these transactions, Alpern's direct beneficial ownership of common stock decreased from 78,587 to 73,587 shares.
• The derivative securities (options) had a vesting schedule where 25% vested on August 26, 2020, and thereafter 1/48th of the total shares vested monthly for 3 years, beginning on September 26, 2020.

Sentiment

Score: 6

Explanation: Slightly positive due to the officer realizing a significant profit from vested equity, indicating value creation for the equity compensation. The transaction being under a 10b5-1 plan mitigates any negative perception of insider selling, suggesting a pre-planned financial management decision rather than a reaction to company performance.

Positives

• The reporting person realized a significant profit by selling shares at a weighted average price of $10.3089 after exercising options at $0.56, indicating a positive return on vested equity.
• The transaction was conducted under a pre-arranged 10b5-1 trading plan, which suggests a planned and not opportunistic sale, providing transparency and mitigating concerns about insider trading.

Negatives

• An officer selling shares, even under a 10b5-1 plan, can sometimes be perceived negatively by some investors, though the pre-planned nature typically lessens this impact.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This is a routine insider transaction disclosure and does not provide information to analyze broader industry trends or competitors. It reflects an individual executive's equity management rather than a company-wide strategic move.

Corporate Governance

Stakeholder Impact

• Shareholders: May note the sale of shares by a key executive, but the context of a pre-arranged 10b5-1 plan generally reduces negative interpretations. The executive profiting from equity compensation can be seen as an alignment of interests and a reward for past performance.

Key Dates

Keywords

Arteris, AIP, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Paul Alpern, Equity Compensation